{"id":23652,"date":"2024-11-20T07:52:06","date_gmt":"2024-11-20T12:52:06","guid":{"rendered":"https:\/\/medicarereport.org\/?p=23652"},"modified":"2024-11-20T07:52:08","modified_gmt":"2024-11-20T12:52:08","slug":"drugmakers-and-pharmacists-battle-over-who-gets-to-make-obesity-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=23652","title":{"rendered":"Drugmakers and pharmacists battle over who gets to make obesity drugs"},"content":{"rendered":"\n<p>(By Sydney Lupkin for NPR)<\/p>\n\n\n\n<p>Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high demand that the drugmakers have had a hard time keeping up. So compounding pharmacies stepped in to fill the gap, making their own versions of the drugs for more than two years.  Continue reading <a href=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/11\/20\/nx-s1-5178102\/ozempic-semaglutide-tirzepatide-compounding-pharmacies\" data-type=\"link\" data-id=\"https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/11\/20\/nx-s1-5178102\/ozempic-semaglutide-tirzepatide-compounding-pharmacies\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"54\" class=\"wp-image-3902\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Sydney Lupkin for NPR) Ozempic and similar drugs for Type 2 diabetes and weight loss are in such high<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21,15],"tags":[458,192,238,1602,504,1601],"class_list":["post-23652","post","type-post","status-publish","format-standard","hentry","category-health-care-finance","category-part-dprescription-drugs","tag-drug-companies","tag-drug-shortages","tag-healthcare-finance","tag-obesity-drugs","tag-ozempic","tag-pharmacists"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23652"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23652\/revisions"}],"predecessor-version":[{"id":23653,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23652\/revisions\/23653"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}